Earnings ·
Scinai Immunotherapeutics reported first-half 2026 results, achieving revenues of $949 thousand and net income of…
SCNIScinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics reported first-half 2026 results, achieving revenues of $949 thousand and net income of approximately $1.6 million, a reversal from the prior year's net loss of $4.1 million. The profit was driven by a $6.4 million bargain purchase gain from the February 2026 acquisition of Recipharm Israel Ltd., which expanded its contract development and manufacturing organization (CDMO) platform. Operating expenses increased due to the acquired Yavne operations, resulting in an operating loss of $4.6 million. The company secured approximately $3.1 million in committed CDMO customer orders and received $650 thousand in advances for an expanded U.S. clinical manufacturing program. Additionally, Scinai announced a one-for-ten reverse split of its American Depositary Shares (ADSs), effective August 21, 2026, increasing the ADS ratio from 4,000 to 40,000 ordinary shares per ADS. The company operates in the biopharmaceutical industry, focusing on innovative immunology therapies and providing CDMO services.